{"disease":{"id":"alk-negative-nsclc","name":"alk negative nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05157776","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT06260553","title":"Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}